Systems biology and combination therapy in the quest for clinical efficacy
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Background
Cited by
Items 501–570 of 570
Korkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Solit, D. B., Pratilas, C. A., et al. (2014) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/008201 · Cited by 1
“One potential solution to overcome drug resistance is to combine targeted drugs to block potential escape routes (Fitzgerald et al., 2006).”
BackgroundKashif, M. (2015) · Uppsala University Publications (Uppsala University) · Cited by 1
Boerries, M., Eils, R., & Busch, H. S. (2011) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200500051.pub2 · Cited by 1
Pritchard, J. R. (2012) · DSpace@MIT (Massachusetts Institute of Technology)
Cellular and Immunological Regulation of Viral Myocarditis
Marchant, D., Farshid, S., & Bruce, M. (2011) · InTech eBooks · doi:10.5772/20845
“Thus, combination therapy may be necessary to achieve efficacy due to less treatment resistance (Fitzgerald et al., 2006).”
BackgroundPaudel, N. (2014) · DSpace@MIT (Massachusetts Institute of Technology)
The chemical and computational biology of inflammation
Small, B. G. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery
Hendriks, B. S. (2011) · Wiley eBooks · doi:10.1002/9781118016435.ch5
Focus on the Fundamentals: Toward Better Therapeutic Index Prediction
Xu, J. J., & Yu, L. J. (2008) · Wiley eBooks · doi:10.1002/9780470431818.ch1
Ho, C. H. (2011) · Library and Archives Canada (Government of Canada) · Cited by 1
Medicinal Inorganic Chemistry: Ligand Design Objectives and Principles
Thompson, K. H. (2011) · Wiley eBooks · doi:10.1002/9781119951438.eibc0365
A Novel Method for Assessing in Vitro Oncology Drug Combinations Using Growth Rates
Pashkevich, M. A., Iversen, P. W., & Brooks, H. B. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.550700
“It is expected that many new oncology treatments will be approved as combination therapies of new compounds with drugs already on the market (Fitzgerald et al., 2006).”
BackgroundINGOT: Towards network-driven in silico combination therapy
Bhowmick, S. S., Chua, H.-E., & Zheng, J. (2014) · International Conference on Big Data and Smart Computing · doi:10.1109/bigcomp.2014.6741401
“Loewe additivity theory [12] can be used to determine synergism by replacing drug dosages in its combination index with target activities.”
MethodQuantifying the activity of anti-HIV treatment in silico
Ribeiro, R. M. (2012) · Nature Medicine · doi:10.1038/nm.2698
Abstract A13: A signaling pathway rationale for the design of combination therapies for cancer
Vera‐Licona, P., Zinovyev, A. Y., Bonnet, É., Kuperstein, I., Kel-Margoulis, O. V., Kel-Margoulis, A., Dubois, T., Tucker, G., & Barillot, E. (2012) · Cancer Research · doi:10.1158/1538-7445.csb12-a13
Owens, C. C., Murali, T. M., & Ramakrishnan, N. (2009) · ACM Symposium on Applied Computing · doi:10.1145/1529282.1529609
“Similar relationships underlie signaling pathway analysis [14] and exploration of therapies for drug discovery [8].”
BackgroundMcClure, N. S. (2013) · QSpace (Queen's University Library)
Griffioen, A. W., Weiss, A., Berndsen, R. H., & Nowak-Sliwinska, P. M. (2014)
Modelling Viral Evolution and Adaptation
Manrubia, S. C. (2015) · Trends in mathematics · doi:10.1007/978-3-319-22129-8_22
“The simultaneous administration of two or more drugs has been used to delay the appearance of resistant mutants [6].”
BackgroundVrana, J. A. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6880 · Cited by 1
Systems Chemical Biology: Integrating Medicinal Chemistry and Systems Biology for Drug Discovery
Wang, R.-S., & Loscalzo, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12334-0
An Introduction to Systems Biology and Quantitative Systems Pharmacology
Gomes, B. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12355-8
Complex Systems Biology of Mammalian Cell Cycle Signaling in Cancer
Avva, J. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Développement d'une méthode pour la détection de cibles secondaires de ligands
Rasolohery, I. (2016) · theses.fr (ABES) · doi:10.70675/eefe2847z3de0z4d25zab7az64f71f8a563c
Feedback System Control: optimizing drug combinations for tuberculosis treatment
Vite, S., & Marlene, A. (2014)
Willaert, R. (2018) · MDPI eBooks · doi:10.3390/books978-3-03897-432-1
Sun, X. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.76185
“A Bliss combination index [54, 55] was used to quantitatively evaluate the synergy produced by BRAF-I and MEK-I co-treatment and BRAF-I and PI3K-I co-treatment as follows:”
MethodZhu, W. (2018) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/d1ya-4356
Population Dynamics of Bacteria Exposed to Antimicrobial Peptides
Baeder, D. Y. (2018) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-b-000337435
Exploring Ethical Issues in Animal Experimentation
Faulkner, A. O., Vasallo, A. K., Wilson, A. R., & Bryan, C. J. (2007) · Digital WPI
Rahman, K. M. T., Islam, M. F., Saha, S., & Billah, M. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.21.436331
Faculty Opinions recommendation of Combinatorial drug discovery in nanoliter droplets.
Djurić, S. W. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733450002.793549194
Hunger, S. P., & Green, A. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726574059.793537563
Medicinal Inorganic Chemistry: Ligand Design Objectives and Principles
Thompson, K. H. (2005) · Wiley eBooks · doi:10.1002/0470862106.ia473
The landscape of non-coding RNA in triple negative breast cancer.Preprint
Mamoor, S. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/k7nwa
Mamoor, S. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/3fc26
Mamoor, S. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/pncxr
Marchi, C., & Martins, D. (2022) · Preprints.org · doi:10.20944/preprints202207.0004.v1
Application of molecular pharmacology in research techniques and drug development
Chakraborty, M., Sarkar, N., Kumari, A., Roy, K., Karunakaran, G., Das, P., Usman, J. A. M., & Karmakar, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99855-0.00024-5
Cirstea, D. D., Hideshima, T., Rodig, S. J., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., Perrone, G., Görgün, G., Patel, K. J., et al. (2023) · doi:10.1158/1535-7163.c.6532194
Gupte, A., Baker, E. K., Wan, S.-S., Stewart, E., Loh, A. H. P., Shelat, A. A., Gould, C. M., Chalk, A. M., Taylor, S., Lackovic, K., et al. (2023) · doi:10.1158/1078-0432.22458170
Gioeli, D. G., Wunderlich, W., Sebolt, J. S., Bekiranov, S., Wulfkuhle, J. D., Petricoin, E. F., Conaway, M. R., & Weber, M. J. (2023) · doi:10.1158/1535-7163.c.6535233
Kashif, M., Andersson, C. R., Åberg, M., Nygren, P., Sjöblom, T., Hammerling, U., Larsson, R., & Gustafsson, M. G. (2023) · doi:10.1158/1535-7163.22499796
DEVELOPMENT OF TARGETED DRUG COMBINATIONS BLOCKING MULTI-DRIVER ONCOGENESIS
Yonchak, A. (2023) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/thesis-yonchak-alexander-2023
Machine Learning Perspective in Cancer Research
Sharma, A., & Rani, R. (2023) · IGI Global eBooks · doi:10.4018/979-8-3693-3026-5.ch047
GENETIC DETERMINANTS OF DRUG RESPONSE IN DIFFUSE LARGE B-CELL LYMPHOMA
Issa, I. I. (2024) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau718060352 · Cited by 1
Two-Dimensional Maximin Power Designs for Combination Experiments of Drugs
Huang, H., & Liu, M. (2024) · Communications in Mathematics and Statistics · doi:10.1007/s40304-023-00388-w
Baaz, M., Cardilin, T., & Jirstrand, M. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106901
Bashir, A. M., Isa, K. A., Danbala, A. A., & Borodo, S. B. (2025) · Trends in Natural Products Research · doi:10.61594/tnpr.v6i1.2025.120
Systems chemical biology: Integrating medicinal chemistry and systems biology for drug discovery
Wang, R. S., Xu, H., & Loscalzo, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00025-x
A statistical framework for defining synergistic anticancer drug interactionsPreprint
Dias, D., Zobolas, J., Ianevski, A., & Aittokallio, T. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.29.679166
İlaç Dirençliliğinde Wnt/Β-Katenin Sinyalizasyonu ve Gstp1 Arasındaki Metabolik Etkileşim
Kılıç, M., & Güneş, B. A. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3862.c1433
Multi-Channel Learning Framework Based on Relation-Aware Transformer For Drug Synergy Prediction
Zhang, K., Huang, Y., Wang, R., Zang, T., & Zhao, Y. (2025) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn64981.2025.11227938
Computational approaches to drug design and treatment optimization in genetic diseases
Doldán-Martelli, V. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
BNIP3-mTOR Signaling Mediates Resistance to MET Inhibition in GlioblastomaPreprint
Li, Y., Khan, H., Demirsoy, Ş., Bernhardt, W., Valensi, H., Lee, J., Machtay, M. X., Aregawi, D. G., Glantz, M. J., Giglio, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.28.696781
“The Bliss difference was calculated as described previously (32).”
Mendes, I., Marques, L., Ribeiro, E., & Vale, N. (2026) · Physchem · doi:10.3390/physchem6010017
“Drug synergy, which refers to the enhanced efficacy of drugs when used in combination, is a key objective in combinational drug development [68].”
Enhancing drug synergy in malignant diseases with deep architecture optimization algorithms
Rani, P., Dutta, K., & Kumar, V. (2026) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2026.2646310
Prague, M. (2013) · theses.fr (ABES) · doi:10.70675/70a6e0bezcfa3z48f2za8a7zce2561b5d39b
Shi, X., & Wang, Q. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.722940
Lazo, J. S. (2026) · ASPET Discovery · doi:10.1016/j.aspetd.2026.100030
Jeong, Y., & Byun, J. H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1834793
MKASynergy: an adaptive method for drug synergy prediction via a mixture-of-experts kernel mechanism
Lin, C., 倪建成, Yang, Y., Zhang, C., & Wang, Y. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00849-6
“Exhaustive experimental screening has become unsustainable in terms of cost, time, and ethics (Fitzgerald et al. 2006; Foucquier and Guedj 2015).”
Jammoul, D., Ajibuwa, F., Jammoul, M., Schlosser‐Hupf, S., Müller, M., & El‐Najjar, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784272
“…systems biology-guided combination design, and ex vivo or disease modeling approaches, among others, all aimed at estimating how disease systems will respond to multiple drugs simultaneously (Zimmer et al., 2017; Fitzgerald et al., 2006; Katzir et al., 2019; Liu et al., 2018; Lam et al., 2018).”
Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma
Li, Y., Khan, H., Demirsoy, Ş., Younis, M., Shi, G., Valensi, H., Bernhardt, W., Lee, J., Machtay, M. X., Aregawi, D., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177780
Xiao, K., Fan, M., Zheng, H., Gu, B., Wang, S., Wu, Z., Zhang, S., Zhao, X., Zhang, W., Ning, Q., et al. (2026) · Smart Molecules · doi:10.1002/smo2.70101
Proteasome inhibition bidirectionally regulates ferroptosis sensitivity
Murray, M. B., Upadhyay, R., Szylo, K. J., Gautam, A., Goncalves, J., Forcina, G. C., Vinayak, A. A., Brandman, O., & Dixon, S. J. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.09.020 · Cited by 1
BindingDB Entry 50032218: New approaches to molecular cancer therapeutics.
BindingDB (2011) · UC San Diego · doi:10.7270/q23t9hf8
BindingDB Entry 50038080: Multi-target-directed ligands to combat neurodegenerative diseases.
BindingDB (2012) · UC San Diego · doi:10.7270/q25b039w
Lammari, N., Louaer, M., Rabti, H., Amichi, H., Ayachi, A. A., Dalia, F., Louaer, O., Méniai, A.-H., Bensouici, C., & Elaïssari, A. (2026) · South African Journal of Botany · doi:10.1016/j.sajb.2026.10.043
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.